Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹689 Cr
verified against source
Revenue YoY
6.11%
reported change
EBITDA
₹237 Cr
latest reported figure
Source
nse announcements
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Alivus Life Sciences delivered a strong Q4 FY26 with revenue of 689 crore (+6.1% YoY) and EBITDA margin of 34.4% (+230 bps YoY), driven by favorable product mix, cost discipline, and non-GPL growth (71% of revenue). Full-year revenue reached 2,552 crore (+6.9% YoY) with EBITDA margin of 33.6% (+366 bps). Management guided EBITDA margins of 30-32% for FY27, citing backward integration benefits from Solapur (operational Q2 FY27) and sustained non-GPL momentum. Key risks include tariff uncertainties, raw material cost inflation from geopolitical tensions, and potential delays in CDMO deal closures.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to sustain EBITDA margins in the range of 30-32% for FY27, despite geopolitical headwinds.
- Planned capex of about 540 crore for FY27, including carryover commitments and fresh investments, fully funded through internal accruals.
- Solapur greenfield facility Phase 1 expected to be operational in Q2 of FY27, with initial capacity utilization of 40-50%.
- Management expects to close two new CDMO deals in the early second half of FY27, continuing momentum.
Risks flagged
- Ongoing geopolitical conflicts and tariff uncertainties could disrupt supply chains and increase logistics and energy costs.
- Solvent costs have increased significantly due to the war, though management expects to pass on costs to customers.
- A fire at the H plant impacted intermediate production, resulting in a 20 crore loss booked in other expenses, with minor spillover expected in Q1.
- Management moderated timing for two CDMO deals to early H2 FY27, indicating possible delays from earlier expectations.
Key quotes
- We expect the contribution from the non-GPL business to continue to increase going forward.
- We remain confident in our ability to sustain EBITDA margins in the range of 30 to 32%.
- Maintaining a high quality business is a much bigger priority for Alivus. Growth will not be pursued at the cost of margins.
Research modules